VIDEO: Pirtobrutinib ‘superior’ for relapsed CLL
SAN DIEGO — In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton tyrosine kinase inhibitor.
"Unsurprisingly, pirtobrutinib [Jaypirca, Eli Lilly & Co.] was superior to the comparator arm in terms of progression-free survival," Woyach, professor in the division of hematology at The Ohio State University, said, noting an important detail to come from this study.
"There is a big discrepancy between progression-free survival and the actual time to next treatment," which was approximately 10 months longer, she said. This suggests that real-world patients treated with pirtobrutinib are relapsing even slower, indicating that the clinical benefit may last longer than seen in the clinical trials, she added.
Reference:
- Sharman JP, et al. Abstract 886. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Collapse
Healio Interviews
Read more about